Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy

Diabetes Care
Antonios DourosLaurent Azoulay

Abstract

Previous studies suggested that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may initially worsen and possibly increase the risk of diabetic retinopathy. However, data on this possible association remain limited. Thus, this population-based study aimed to determine whether use of GLP-1 RAs is associated with an increased risk of incident diabetic retinopathy. Using the U.K. Clinical Practice Research Datalink (CPRD), we conducted a cohort study among 77,115 patients with type 2 diabetes initiating antidiabetic drugs between January 2007 and September 2015. Adjusted hazard ratios (HRs) and 95% CIs of incident diabetic retinopathy were estimated using time-dependent Cox proportional hazards models, comparing use of GLP-1 RAs with current use of two or more oral antidiabetic drugs. In an ancillary analysis, new users of GLP-1 RAs were compared with new users of insulin. During 245,825 person-years of follow-up, 10,763 patients were newly diagnosed with diabetic retinopathy. Compared with current use of two or more oral antidiabetic drugs, use of GLP-1 RAs was not associated with an increased risk of incident diabetic retinopathy overall (HR 1.00, 95% CI 0.85-1.17). Compared with insulin, GLP-1 RAs were associated with a d...Continue Reading

References

May 1, 1989·Statistics in Medicine·S Durrleman, R Simon
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Apr 23, 1999·Lancet·T Walley, A Mantgani
Jan 30, 2002·Diabetes Care·Marianne HenricssonGöran Sundkvist
Oct 31, 2003·American Journal of Epidemiology·Wayne A Ray
Aug 4, 2005·Retina·Daniel E GoldbergWilliam R Freeman
Dec 7, 2007·American Journal of Epidemiology·Samy Suissa
Feb 25, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·A M S Brooks, C A Lissett
Jan 19, 2010·British Journal of Clinical Pharmacology·Emily HerrettAndrew J Hall
Sep 13, 2011·Diabetes Research and Clinical Practice·Lakshminarayanan VaradhanGeorge I Varughese
May 11, 2012·Pharmacoepidemiology and Drug Safety·Robert J GlynnSebastian Schneeweiss
May 4, 2013·Drugs·Olga E MakriConstantine D Georgakopoulos
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Jan 25, 2014·Diabetes Research and Clinical Practice·Lakshminarayanan VaradhanGeorge I Varughese
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jan 26, 2016·Current Medical Research and Opinion·Louis S MatzaKristina S Boye
Feb 4, 2016·Epidemiology·Peng Ding, Tyler VanderWeele
Mar 5, 2016·Journal of Clinical Epidemiology·Hiraku KumamaruSebastian Schneeweiss
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Oct 22, 2016·Diabetes & Metabolism Journal·Dora M GormanNeil G Docherty
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Feb 13, 2018·BMJ Open Diabetes Research & Care·Susanne RöcklChrista Scheidt-Nave

❮ Previous
Next ❯

Citations

May 31, 2019·Metabolic Syndrome and Related Disorders·Ajay Sood, Arthur Swislocki
Oct 8, 2019·The Journal of Clinical Endocrinology and Metabolism·Bénédicte GaboritStéphane Germain
Aug 3, 2020·JAAPA : Official Journal of the American Academy of Physician Assistants·Ji Hyun Chun, Amy Butts
Aug 7, 2020·JAAPA : Official Journal of the American Academy of Physician Assistants·Ji Hyun Chun, Amy Butts
Jun 25, 2020·International Ophthalmology Clinics·Ella H Leung, Janet H Leung
Feb 27, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Thomas M CaparrottaHelen M Colhoun
Aug 7, 2021·Journal of Clinical Pharmacy and Therapeutics·Weiyun QianQichao Yang
Dec 18, 2021·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Thomas Arendt NielsenChristina Brock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.